a b s t r a c t E3 ligases are essential scaffold proteins, facilitating the transfer of ubiquitin from E2 enzymes to lysine residues of client proteins via isopeptide bonds. The specificity of substrate binding and the expression and localization of E3 ligases can, however, endow these proteins with unique features with variable effects on mitochondrial, metabolic and CNS function. By comparing and contrasting two E3 ligases, Parkin and C-terminus of HSC70-Interacting protein (CHIP) we seek to highlight the biophysical properties that may promote mitochondrial dysfunction, acute stress signaling and critical developmental periods to cease in response to mutations in these genes. Encoded by over 600 human genes, RING-finger proteins are the largest class of E3 ligases. Parkin contains three RING finger domains, with R1 and R2 separated by an in-between region (IBR) domain. Loss-of-function mutations in Parkin were identified in patients with early onset Parkinson's disease. CHIP is a member of the Ubox family of E3 ligases. It contains an N-terminal TPR domain and forms unique asymmetric homodimers. While CHIP can substitute for mutated Parkin and enhance survival, CHIP also has unique functions. The differences between these proteins are underscored by the observation that unlike Parkin-deficient animals, CHIP-null animals age prematurely and have significantly impaired motor function. These properties make these E3 ligases appealing targets for clinical intervention. In this work, we discuss how biophysical and metabolic properties of these E3 ligases have driven rapid progress in identifying roles for E3 ligases in development, proteostasis, mitochondrial biology, and cell health, as well as new data about how these proteins alter the CNS proteome.
Discovery of Parkin and the role of mitochondria in neurodegeneration

Parkinson's disease
Parkinson's disease is an age-related neurodegenerative disease characterized by loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The resulting changes in dopaminergic tone within the basal ganglia cause hallmark symptoms of PD including cognitive decline, akinesia, bradykinesia and tremor. Approximately 10% of PD patients have inherited mutations in genes including: SNCA, LRRK2, PARK2, PARK7, and PINK1; however, the vast majority of PD is sporadic in nature, with no known family history (Klein and Westenberger, 2012 ). Parkinson's is the second most prevalent neurodegenerative disease in the world affecting approximately 9,000,000 patients (Dorsey et al., 2007) . Risk factors for sporadic PD include age, sex (males have a 1.5 time greater likelihood of developing PD), exposure to pesticides and fungicides, and contact with other environmental toxins (Gorell et al., 1997 (Gorell et al., , 1998 Taylor et al., 2007; Van Den Eeden et al., 2003) . Individuals who have suffered concussive brain injury, most notably from participating in football, hockey, boxing and mixed-martial art combat, have a higher incidence of PD and PD-like symptoms (Gardner et al., 2015; Mez et al., 2017; Pearce et al., 2015) .
The selective vulnerability of SNpc neurons to PD-induced degeneration has been linked to unique intrinsic properties of affected dopaminergic cells as well as circuit-specific factors, such as requirements in firing activity, afferent neurochemical input and other regional specific features of the SNpc (Surmeier et al., 2017) .
One particularly appealing hypothesis first put forth by Jim Surmeier in 2010, incorporates aspects of these cell and circuit specific changes. This model features a critical role for the pacemaking properties of L-type calcium channels, whereby mitochondrial buffering of calcium entry through these channels increases mitochondrial oxidant production (Surmeier et al., 2010 (Surmeier et al., , 2011 . The unique expression and activation of these channels may, therefore, place SNpc calcium buffering systems in peril. This hypothesis is consistent with an important primary role for mitochondrial failure in mediating Parkinson's pathology. This idea, first hypothesized in the 1970s (Ahlqvist et al., 1975) , continues to evolve based on our understanding of the newest genes and mutations that are associated with PD.
Prior to widespread genetic analysis, the earliest and most reliable models of Parkinson's disease were developed by the labs of Flint Beal, Bill Langston and Tim Greenamyre using peripheral and central administration of pesticides, herbicides, drugs of abuse, and other agents (Beal and Lang, 2006; Betarbet et al., 2002; Schlossmacher et al., 2002) . While compounds that induced PDlike degeneration and motor symptoms were structurally unique, they shared the underlying biochemical property of blocking aerobic respiration (Tipton and Singer, 1993) . Taken together with data from patient fibroblasts and imaging, these groundbreaking studies supported a central role of mitochondrial number, bioenergetic function, integrity and signaling in disease pathology (see reviews (Ding and Yin, 2012; Kang et al., 2016; Moon and Paek, 2015; Wang et al., 2016) ).
Mitochondrial dynamics and quality control
Genetic linkage of Parkin and other genes has continued to reinforce a critical role for defects in mitochondrial dynamics, energetics and localization as a primary cause of PD. Genetic mutations in Parkin were linked to PD in a 1998 study by Kitada and colleagues who evaluated patients exhibiting very early onsettypically between 18 and 27 years of age compared to the average age of onset in the general population which is 60 . Within six years of publishing their paper linking a handful of point mutations in Parkin to PD, researchers had isolated 127 unique mutations in the Parkin protein Hedrich et al., 2004) .
Parkin relocalizes to the mitochondrial outer membrane during environmental, oxidative or bioenergetic stress (Darios et al., 2003; Islam, 2017; Narendra et al., 2008) . The mitochondrial membrane consists of two bilayers -an inner and outer membrane -that separate distinct environments and exhibit specific protein and lipid compositions. The outer mitochondrial membrane (OMM) is enriched in pro-and anti-apoptotic proteins, protein translocases and phosphotidylcholine, while the inner mitochondrial membrane (IMM) is enriched in cardiolipin and roughly 70 other proteins (Comte et al., 1976) .
Each neuron must generate, repair, and replace hundreds to thousands of biologically active mitochondria in order to supply sufficient ATP and calcium buffering capacity to ensure cell viability (Chan, 2012; Chang and Reynolds, 2006; Erecinska and Silver, 1989; Golpich et al., 2017) . Therefore, it is not difficult to envision why the demands of constant de novo mitochondrial biogenesis are overwhelming, compelling mitochondria to be able to combine resources via fission and fusion or to isolate functional mitochondria from those that need to be recycled via autophagic processes.
Mitofusin 1 (Mfn1) and Mitofusin 2 (Mfn2) assist in the fusion of OMMs, while Optic Atrophy 1 (Opa1) permits fusion of IMMs (Chen and Chan, 2009 ). The fusion of mitochondrial membranes between organelles promotes ionic buffering and sharing of energetic resources. Indeed, stress-induced hyperfusion of mitochondria is a highly effective way for neurons to promote cell survival under acute stress whereas under normal conditions, cells are able to segregate damaged mitochondria (Chen and Chan, 2009 ). Hyperfusion occurs within minutes to hours after acute stress resulting in a highly interconnected mitochondrial network that enhances communication with the endoplasmic reticulum (van der Bliek, 2009). Fusion also allows diffusion of matrix content among mitochondria, diluting accumulated mitochondrial DNA mutations and oxidized proteins (Archer, 2013) .
Cortical neuronal mitochondria have been the most widely studied primary neuronal culture system for mitochondrial dynamics. Mitochondria have equal fusion-fission and fission-fusion cycle rates of 0.023 cycles per mitochondrion per minute, or roughly one cycle completed for a single mitochondrion every 43 min (Cagalinec et al., 2013) . In models of proteotoxicity in which mutant Huntington or Tau are overexpressed, mitochondrial fusion rates decrease, and mitochondria become shortened (Cagalinec et al., 2013) . This is reversible by overexpression of the mitochondrial motility protein Miro (Cagalinec et al., 2013) . While fusion rates depend on mitochondrial motility, fission rates depend on mitochondrial length. In cortical neurons, mitochondria will undergo fission more frequently when mitochondrial length exceeds 4 mm (Cagalinec et al., 2013) . This constant cycling of mitochondrial fission and fusion is tightly regulated and subject to changes in the cellular proteome.
Parkin is a critical mediator of mitochondrial fission and fusion, as well as mitophagy, which we will discuss in further detail (Narendra et al., 2008 (Narendra et al., , 2012 . The only other E3 ligase known to compensate for loss of function Parkin mutations is C-terminus of HSC70-Interacting Protein (CHIP) which can promote proteostasis when Parkin is mutated or absent (Imai et al., 2002) . Interactions between CHIP and Parkin have also been previously reviewed by Kumar et al., particularly in the context of aberrant signaling in Alzheimer's disease (Kumar et al., 2012) , and we will expand on this body of literature by discussing overlapping mitochondrial functions of these E3 ligases later in this review.
Stress-induced regulation of mitochondria
Rates of mitochondrial fission and fusion are closely linked to changes in metabolism (Buhlman et al., 2014; Gomes et al., 2011a,b; Liu and Hajnoczky, 2011) . Mitochondria fuse when they are forced to rely on oxidative phosphorylation or during nutrient depletion (Gomes et al., 2011a,b; Rossignol et al., 2004) . This increased fusion is hypothesized to maximize the efficiency of oxidative phosphorylation by stimulating complementation of healthy and ailing mitochondria (Youle and van der Bliek, 2012) .
Starvation-induced autophagy may evoke stress-induced mitochondrial hyperfusion, or it may inhibit fission to protect mitochondria from autophagic catabolism when they are most needed (Youle and van der Bliek, 2012) . Fission creates compact mitochondria generating high levels of ROS, facilitating mitophagy and accelerating cell proliferation. Hyperactive fission has been implicated in PD pathology (Santos et al., 2015) . Alternatively, cells that are deficient in the critical fission molecule dynamin-related protein 1 (Drp1) have fewer dopaminergic terminals in regions impacted by PD including the caudate-putamen. This loss of dopaminergic connections ultimately results in a loss of cell bodies in the midbrain (Berthet et al., 2014) .
Genetic models for understanding Parkin function
Several groups simultaneously reported that mutations of the Parkin gene in mice failed to capture the age-dependent motor, cognitive and pathological features of clinical PD Kitada et al., 2009; Varcin et al., 2012) . Introducing Parkin mutations in Drosophila did, however, induce a tubular mitochondrial morphology that correlates with failed mitochondrial entry into axons (Greene et al., 2003; Sung et al., 2016) . Under physiological stress, Drosophila expressing mutant Parkin fail to promote autophagic degradation of mitochondria , underscoring the significant gaps in our understanding of the multitude of processes corrupted by PD in different animal models.
Introduction of mutations in Parkin concomitant with mutations in other genes associated with familial PD were somewhat more successful in mouse models, altering neurochemistry and cell biology in a manner consistent with PD. Endosomal, lysosomal and mitochondrial abnormalities have been described in triple knockout mice; yet, these effects still result in modest neurodegenerative phenotypes (Kitada et al., 2009) . To fill these gaps in modeling PD genetic mutations, scientists have redoubled their efforts at uncovering Parkin's role in proteostasis as well as searching for other factors that may predispose dopaminergic cells to die in PD. In doing so, studies of Parkin's structure revealed its role in the ubiquitination of substrate proteins.
E3 ligase structure and function
Conservation of ubiquitination as a critical regulator of protein function from yeast to humans underscores the importance of this post-translational modification for eukaryotic life. Over the past two decades, ubiquitin has been linked to apoptosis, facilitating protein-protein interactions, promoting DNA transcription and cell repair (Grabbe et al., 2011; Hammond-Martel et al., 2012; Husnjak and Dikic, 2012; Zhao et al., 2014) .
During the ubiquitination process, E1 enzymes activate ubiquitin via an ATP-dependent reaction, forming a thioester with ubiquitin's C-terminus. The activated ubiquitin is then transferred to a cysteine residue of an E2 ubiquitin conjugating enzyme. E3 ligases then carry out the final step in the ubiquitination cascade, catalyzing the transfer of ubiquitin from the E2 enzyme to a lysine residue of the substrate in a covalent manner (Reviewed by (Metzger et al., 2012) ).
Three classes of E3 ligases facilitate this ubiquitin transfer by different mechanisms and are distinguished by their unique structural features. They are: the RING, the HECT, and the ringbetween-ring (RBR) E3 ligase proteins. RING family proteins catalyze the transfer of ubiquitin directly from an E2 enzyme to the substrate, whereas the HECT and RBR families facilitate the transfer of ubiquitin via a two-step trans-thioesterfication reaction (Metzger et al., 2012) .
Parkin is a redox-sensitive RING finger domain E3 ligase
Parkin is unique in that the structure of the protein suggests that it is a classical RBR, yet based on cell free assays as well as in situ studies, it contains features of both RING and HECT E3 ligase activity (Riley et al., 2013) . Notably, ligases containing the structures necessary for the trans-thioesterification reactions during ubiquitin transfer are more susceptible to changes in cell redox status (Groitl and Jakob, 2014; Riley et al., 2013) .
Parkin is rich in methionine and cysteine residues, which are the most vulnerable amino acids to oxidative modification (Halliwell and Gutteridge, 1989) , and HECT domains often contain multiple cysteine residues needed for trans-thioesterification (Kee and Huibregtse, 2007) . Disruption of these catalytic residues by reactive oxygen species (ROS) has been shown to slow or halt substrate ubiquitination (Doris et al., 2012) . Taken together, these data suggest that there are structural features of Parkin that make it uniquely vulnerable to aberrant redox modification or uniquely sensitive to detecting changes in redox environment as a mechanism to control bioactivity of the ligase.
It has been hypothesized that one factor that could contribute to the early death of SNpc neurons in PD is the high level of ROS produced in these cells (Choi et al., 2003) . One particularly elegant feedback loop that speaks to the unique nature of dopaminergic cells in the SNpc, as well as Parkin's role in neuronal redox homeostasis, exists between Parkin and a novel transcription factor named Parkin Interacting Substrate (PARIS, ZNF746), which was identified in 2011 by Ted and Valina Dawson (Shin et al., 2011) . Mitochondrial biogenesis is spurred by transcriptional activation of PGC-1a and NF-E2-related factor (NRF-1) . PARIS controls both of these proteins and is a KRAB and zinc finger protein that accumulates in eukaryotic models in which Parkin is inactivated or deleted, as well as in the brains of patients with PD (Shin et al., 2011) . By binding to insulin response sequences in the PGC-1a promoter, PARIS represses the expression of both PGC-1a and NRF-1.
Conditional knockout of the Parkin protein in mice leads to a progressive loss of dopamine neurons that is PARIS-dependent (Stevens et al., 2015) . Likewise, overexpression of PARIS leads to the selective loss of DA neurons in the SNpc, which is reversed by either Parkin or PGC-1a overexpression. Additionally, familial PDassociated mutations in the RING1 or RING2 domains of Parkin result in diminished binding to PARIS as compared to WT Parkin (Stevens et al., 2015) . The ROS sensitivity of zinc finger proteins suggests that PARIS expression or activity can be altered in either sporadic or inherited PD leading to devastating downstream events, including the inability to renew pools of mitochondria and degrade proteins via the proteasome.
In addition to the conserved RING1, IBR and RING2 domains, Parkin also contains an N-terminal ubiquitin-like (UBL) domain followed by a zinc-binding domain called RING0 (Hristova et al., 2009) . Both the IBR and RING2 domains bind zinc in a similar topological manner, but differ from the canonical cross-brace fold conformation of RING1. The five domains of Parkin associate in a compact arrangement in which the RING0 domain occludes the active cysteine site of RING2, thus auto-inhibiting its activity (Byrd and Weissman, 2013 ).
Parkin's RING finger domains are additional sites of potential structural vulnerability given that within a globular conformation, it binds two zinc ions in a histidine-and cysteine-rich motif. This structure promotes protein-protein interactions, but is also biochemically unstable and prone to oxidation as well as metal displacement by other divalent cations like cadmium and cobalt. The resulting changes in protein structure and function can be rapid, extremely unstable and lead to potentially toxic loss or gain of function alterations in activity (Hartwig, 2001) . Indeed, metal ion disequilibrium has been implicated in environmental toxin induced Parkinson's disease (Gorell et al., 1997; Kwakye et al., 2016) .
Through its C-terminal RING domain, Parkin is able to conjugate to a variety of E2 proteins. For example, UbcH7 and UbcH8 mediate K48-linked poly-ubiquitination that promotes proteasomal degradation, whereas UbcH13 mediates K63-linked poly-ubiquitinationa post-translational modification with a currently unknown role in protein degradation (Imai et al., 2002; Olzmann and Chin, 2008; Shimura et al., 2000) . The proteins and cofactors that regulate binding of Parkin with each of its E2 proteins in vivo remain poorly understood yet are of great importance, given that the ability of Parkin to bind unique combinations of E2 proteins regulates the fate of ubiquitinated clients (Fiesel et al., 2014) . Interestingly, several disease-associated mutations in PARK2 impair E3 ligase activity for a selective population of substrates, including growth factors, repair enzymes, and structural proteins (Imai et al., 2002; Shimura et al., 2000; Zhang et al., 2000) .
Pathogenic mutations in Parkin
Most of the pathogenic mutations in PD patients occur in the linker region between the UBL and RING1 domains. Indeed, mutations in this region account for 43% of identified Parkin pathological changes (Parkinson's Disease mutations database); however, pathogenic mutations have been identified throughout the Parkin protein (Trempe et al., 2013) (Fig. 1) . For example, the RING1 mutant C289G, the RING2 mutant C441R, and the UBL mutant R42P all fail to translocate to depolarized mitochondria (Hampe et al., 2006; Lazarou et al., 2013; Lee et al., 2010) . On the other hand, the RING1 domain mutant R275W is recruited to mitochondria via a PINK1 dependent pathway yet fails to induce mitophagy (Geisler et al., 2010; Narendra et al., 2010) , while mutants deficient in E3 ligase activity, such as A240R and T415N, not only associate with depolarized mitochondria but also induce formation of mitochondrial aggregates Sriram et al., 2005; Zhang et al., 2000) .
Mutations have also been found to increase E3 ligase activity of Parkin (Riley et al., 2013; Trempe et al., 2013) , suggesting that the substrates with which Parkin interacts, the efficacy in which substrates are tagged with ubiquitin and delivered to the proteasome for degradation, and other aspects of function and localization of this protein are critical determinants of dopaminergic cell survival (Seirafi et al., 2015) .
A testament to this complexity is that not all Parkin substrates accumulate in Parkin knockout (KO) mice or PD patients, suggesting that either Parkin-mediated ubiquitination can be independent of proteasomal degradation or that redundant E3 ligases, such as CHIP, can promote proteostasis when Parkin is mutated or absent Imai et al., 2002; Moore et al., 2008; Schlossmacher et al., 2002) .
CHIP is an essential U-box domain E3 ligase
In 2002, Imai and colleagues demonstrated that Parkin associates with Heat Shock Protein 70 (HSP70), where it facilitates ubiquitination and degradation of HSP70 client proteins. Interestingly, this interaction is interrupted by expression of the HSP70 cochaperone and E3 ligase, CHIP. Upon dissociation from HSP70, Parkin can instead focus on turnover of the Pael-R receptors and presumably other substrates during ER-stress (Imai et al., 2002) . Since it was discovered, interest in CHIP has rapidly expanded to PD and other neurodegenerative diseases (Joshi et al., 2016; Kumar et al., 2012) .
CHIP is a 303 amino acid protein that is highly conserved across species (Ballinger et al., 1999) . CHIP was originally discovered in a screen of tetracopeptide repeat (TPR) domain-containing enzymes, of which many participate in interactions with the heat shock protein (HSP) family (Ballinger et al., 1999) . CHIP contains a Nterminal TPR domain, a charged central domain, and a highly conserved C-terminal U-box domain that is necessary for its E3 ligase activity (Ballinger et al., 1999; Jiang et al., 2001) (Fig. 1) .
U-box E3 ligases are far less abundant than RING-finger proteins, with only seven identified in the human and mouse proteomes to date (Hatakeyama et al., 2001) . The U-box domain is functionally and structurally similar to RING domains, but contains a hydrophobic core that lacks metal-chelating residues present in RING domain E3 ligases (Aravind and Koonin, 2000) . One possibility is that this unique structure renders U-box E3 ligase activity resistant to oxidative modification.
In keeping with this hypothesis, we and other groups have reported that CHIP expression is necessary for animals to thrive (McLaughlin et al., 2012; Min et al., 2008) . Mice that lack CHIP are short-lived and exhibit motor dysfunction and cardiovascular abnormalities (McLaughlin et al., 2012; Schisler et al., 2013) . Neurons cultured from CHIP KO animals have increased levels of oxidized proteins and lipids and are more susceptible to acute, mitochondrial stressors (Palubinsky et al., 2015) .
3. Substrates for Parkin-mediated ubiquitination: setting the stage for signaling and structural failure Parkin-mediated ubiquitination tags a diverse set of clients with roles in cell morphology, structure, biochemistry and transcription, as well as proteins essential for proteasomal function. While no single substrate has been identified that leads to PD pathology, studying the list of Parkin substrates reveals a number of themes whereby substrates reinforce a primary role for Parkin in proteotoxicity (a-synuclein, synphilin-1, PaelR and Eps15), chaperone biology (HSP70) and bioenergetic/mitochondrial dysfunction (Miro, Mfn1 & 2 and Drp1 (Kumar et al., 2012) ). Given that Parkin KO mouse models fail to exhibit a profound motor phenotype, it is likely that substrates of CHIP-mediated ubiquitination differ from, as well as compensate for, Parkin deficiency (Kumar et al., 2012) .
Parkin regulation of protein aggregation and Lewy body formation
Inhibitors of mitochondrial respiration and protein quality control rapidly recruit Parkin to mitochondria (reviewed in (Pickrell and Youle, 2015) ). Yet, Parkin's E3 ligase and quality control capabilities extend beyond mitochondria. A primary component of Lewy bodies, which are found in both inherited and sporadic forms of PD, is a-synuclein, which is targeted by Parkin for proteasomemediated degradation (Kumar et al., 2012; Shimura et al., 2001; Xiong et al., 2009) . Parkin can also ubiquitinate the a-synuclein interacting protein, synphilin-1, in a proteasome-independent manner involving (K63)-linked poly-ubiquitination .
Interestingly, this K63-mediated mode of ubiquitination by Parkin enhances the formation of Lewy-body-like inclusions formed by co-expression of synphilin-1 and a-synuclein ). Lim and colleagues attribute this dual fate to the stoichiometry of Parkin to synphilin-1, in that high Parkin expression is capable of promoting synphilin-1 turnover (4:1 expression ratio), when cells are primed for K48-linked ubiquitination (Lim et al., Fig. 1 . Examples of E3 ligase families with mutations known to cause CNS disorders. E3 ligases are broken down into three main classes: HECT, RING finger, and RBR. The HECT and RBR families facilitate the transfer of ubiquitin via a two-step transthioesterfication reaction. Members of the RING finger family (which include Ubox domain-containing enzymes) act as scaffolds between E2 enzymes and the substrate. Mutations in NEDD4-2 of the HECT family were identified in patients with photosensitive generalized epilepsy. NEDD4-2 is proposed to regulate cell surface expression of several ion channels, receptors, and transporters involved in neuronal excitability. STUB1 is the gene that encodes CHIP, an E3 ligase of the RING family with a C-terminal Ubox domain. Several pathogenic mutations were identified in CHIP in patients with particular forms of Spinocerebellar Ataxia (SCA). Mutations are located throughout the protein, suggesting loss of E3 ligase function is not the only important domain in this protein. The PARK2 gene contains few mutations in its ubiquitin ligase domain; most of the mutations appear in its RING domains, which bind two zinc ions in a histidine and cysteine-rich motif to facilitate the transthioesterfication reaction.
2005). Opposingly, when the functional pool of Parkin is low, K63-mediated ubiquitination and subsequent Lewy body formation is favored .
Synphilin-1 interacts with PINK1, (discussed later in section "Structural Determinants of Parkin Regulation of Mitochondrial Quality Control") a kinase that facilitates mitophagy, in a Parkinindependent manner (Szargel et al., 2016) . Overexpression of synphilin-1 causes mitochondrial membrane depolarization and subsequent mitophagy through the seven in absentia homologue (SIAH), a RING finger E3 ligase that targets mitochondrial fission, fusion, and scaffolding proteins (Szargel et al., 2016) . These data support a critical role for the relative concentration of substrates and Parkin in which conditions of low Parkin expression may promote other E3 ligase binding to Parkin clients to avert mitochondrial dysfunction (Szargel et al., 2016) .
A role for Parkin-mediated mitophagy in primary mitochondrial disease
Mitochondria with normal genomes replicate within cells alongside those with deleterious mutations (Holt and Reyes, 2012) . As such, E3 ligases with the ability to selectively remove damaged or dysfunctional mitochondria would result in a mitochondrial population with fewer mutations over time e selecting or enriching for non-mutated mtDNA. For example, long-term overexpression of Parkin eliminates mitochondria with deleterious COXI mutationssuch as those seen in Leigh's Syndrome -in heteroplasmic cybrid cells, thereby enriching cells for wild-type mtDNA and restoring cytochrome c oxidase activity ). This more favorable wild-type to mutant mitochondrial genome ratio is stably maintained even after relieving cybrid cells of Parkin overexpression. These data support a model in which Parkin functions in a mitochondrial quality control pathway. Additionally, the researchers suggest that transiently increasing levels of Parkin expression might ameliorate certain mitochondrial diseases . Similarly, we have recently found that CHIP rapidly relocalizes to damaged mitochondria where it too plays a role in their removal via mitophagy (Palubinsky et al., 2015) .
CHIP mutations result in unique and devastating neurological dysfunction
One might suspect a Parkin surrogate would have mild pathological features when deleted, similar to Parkin-null mice. In fact, quite the opposite is true. Severe motor impairments, mitochondrial failure, cardiovascular abnormalities, and early lethality observed in CHIP deficient animals suggest that this protein plays a critical role in aging, stress responsiveness and neurological function (Palubinsky et al., 2015) . These features stand in stark contrast to Parkin-null mice, which are long-lived and free of major hallmarks of PD or other degenerative diseases (Rial et al., 2014) . Under conditions of energetic and oxidative stress, heat stress and hypoxia we, and others, have shown that CHIP expression is rapidly upregulated (Dai et al., 2003; Kim et al., 2005; Stankowski et al., 2011) .
Within the past five years, whole-exome sequencing has led to the discovery of a number of missense mutations in CHIP in patients with recessive ataxia (Bettencourt et al., 2015; Heimdal et al., 2014; Shi et al., 2014; Synofzik et al., 2014) (Fig. 1) . Patients with recessive ataxia and spinocerebellar ataxia exhibit a progressive loss of motor control, gait abnormalities, and cerebellar atrophy (Heimdal et al., 2014; Shi et al., 2014) . More recently, homozygous mutations in the STUB1 gene encoding CHIP resulting in a loss of function in CHIP activity have been linked to the rare genetic disorder Gordon Holms Syndrome in which patients present with hypogonadism and ataxia (Rubel et al., 2015; Shi et al., 2014) . These phenotypes in humans are consistent with our observations in which male CHIP-deficient mice are infertile. Lastly, there are overlapping patterns of metabolic dysfunction in CHIP deficiency that bear striking similarities to Leigh's syndrome (Lake et al., 2015 (Lake et al., , 2016 .
In humans Leigh's syndrome is a rare (one in 40,000 births), severe neurological disorder that presents between three and twelve months of age. In 80e99% of cases the following are reported: abnormality of movement, muscle hypotonia, and ataxia (Gerards et al., 2016) , which are found in CHIP KO mouse models (McLaughlin et al., 2012) . Characterized by progressive mental disability and psychomotor regression Leigh's syndrome typically results in death within two to three years of life, often as a result of respiratory failure (Lake et al., 2015 (Lake et al., , 2016 ).
Leigh's syndrome is most commonly associated with mtDNA mutations involving genes responsible for properly functioning metabolic enzymes such as pyruvate dehydrogenase and OXPHOS complexes, specifically complex I (cytochrome oxidase) and complex V (MT-ATP6) (Carelli and Chan, 2014; Schon et al., 2012) . These metabolic enzymes are also critical for maintaining IMM biogenesis and formation of cristae (Paumard et al., 2002; Strauss et al., 2008) , and electron micrographs of fibroblasts cultured from a patient with Leigh syndrome reveal loss of cristae ultrastructure and mitochondrial hyperfusion, resulting in premature cellular senescence (Janer et al., 2016) .
CHIP targets mitochondrial enzymes
CHIP contains a TPR binding domain that is responsible for binding with high affinity to heat shock protein chaperones HSC70 and HSP70 and polyubiquitinating client proteins (Assimon et al., 2015) . Until recently, CHIP-specific substrates were ill-defined and limited to known HSC/HSP70 client proteins identified using immunoprecipitation experiments that fail to capture in vitro interactions (Kumar et al., 2012; Stankiewicz et al., 2010) . In the absence of comprehensive proteomic screening, we were unable to develop hypotheses that captured the critical physiological pathways that contribute to the phenotype of CHIP-deficient animalsbut in which mutations did not alter in vivo physiology -and compare it to other E3 ligase proteins. In performing the first proteomic screens of whole brain samples from WT and CHIP KO mice, we sought to provide more accurate and robust signaling signatures of CHIP deficiency and pathology. These experiments were done using samples from age matched in vivo CNS tissues from post-natal day 35 animals, which is more relevant than proteomic analysis of changes that could be attributed to in vitro artifacts like passage number and results from off-target tissues like fibroblasts (Hughes et al., 2007) . For the purposes of this review, the most salient group to which we compared our proteomic data was 2-month-old Parkin KO animals analyzed by Periquet and colleagues (Periquet et al., 2005) , which had modest neurochemical changes associated with PD, but no pathological or motor phenotype (Periquet et al., 2005) .
Our proteomic analysis of CHIP KO whole brains revealed significant changes in the expression of proteins involved in energetic homeostasis and ATP production ( Fig. 3A and B) , several of which are implicated in severe metabolic diseases. For example, loss of CHIP increases lactate dehydrogenase (LDH) and decreases pyruvate dehydrogenase (PDH). During normal glycolysis, LDH reversibly catalyzes the conversion of lactate to pyruvate. Next, pyruvate enters mitochondria through mitochondrial pyruvate carrier proteins (MPCPs) where PDH catalyzes the conversion of pyruvate to acetyl CoA, generating NADH and CO 2 in the process. Acetyl CoA is then further processed via the Krebs cycle or for fatty acid synthesis.
We suspect that elevated LDH may be due to either: 1. CHIP acting as an E3 ligase for LDH degradation, or 2. LDH compensating for decreased PDH, although ultimately unable to reverse the severe impairment in ATP generation that we observe in CHIP KO mice (Palubinsky et al., 2015) . Decreased PDH, along with decreased MCPC1 and MCPC2, reduces the total acetyl CoA production required for the Krebs cycle and ultimately ATP synthesis. Interestingly, PDH deficiencies result in lactic acidosis, and mutations in PDH subunits are a common cause of Leigh's encephalopathy particularly in male patients (De Meirleir, 2002; Patel et al., 2012) . Given these phenotypes, we infer that CHIP is a key regulator of neuronal energetic homeostasis and development.
Our proteomics data of CHIP KO animals also reveals that in addition to regulating glycolytic enzymes there are decreases in Krebs cycle proteins -notably, 2-oxoglutarate dehydrogenase (also known as a-ketoglutarate dehydrogenase) and D-2-hydroxyglutarate dehydrogenase -as well as the complex 1 assembly protein FAD-dependent oxidoreductase protein 1 (FOXRED1). D-2-hydroxyglutarate dehydrogenase catalyzes the oxidation of D-2-hydroxyglutarate to generate 2-oxoglutarate (aketoglutarate). Alpha-ketoglutarate dehydrogenase then catalyzes the conversion of 2-oxoglutarate to succinyl-CoA for further processing through the Krebs cycle. FOXRED1 is necessary for respiratory complex I assembly in the electron transport chain (ETC), which utilizes electron carriers NADH and FADH 2 generated by the Krebs cycle to produce ATP (Formosa et al., 2015) . The decreased expression of these key Krebs cycle enzymes and FOXRED1 are consistent with our data in which CHIP KO animals have significantly decreased ATP and ADP compared to wild-type mice (Palubinsky et al., 2015) . Furthermore, the decrease in complex I function is yet another similarity with Leigh's syndrome (Gerards et al., 2016) , as well as with some forms of Parkinson's disease and hypertrophic cardiomyopathy (Kirby et al., 1999; Schapira et al., 1989) . Given these examples of decreased protein expression in CHIP KO mice, we suspect that CHIP either regulates these proteins in a novel way that does not depend on E3 ligase function, or does so through turnover of enzymes that negatively regulate expression these proteins. Dopaminergic neuronal lines derived from PD patient induced pluripotent stem cells (iPSCs) reveal increases in 25 and decreases in 20 mitochondrial genes (Shaltouki et al., 2015) . In proteomic screens of Parkin KO mouse cortex, 46 proteins with varied roles in energy metabolism (glycolysis, ATP synthesis, NAD/NADP) and protein processing pathways (heat shock protein chaperones, proteasomal components) were identified (Periquet et al., 2005) . Most notably, cortices from Parkin KO animals were found to exhibit a three-fold decrease in the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which is normally induced by oxidative stress and mediates the cell stress response (Dastoor and Dreyer, 2001) . These data suggest that Parkin-deficient cells are unable to sense and respond to redox imbalance.
The goal of comparing Parkin and CHIP proteomic profiles is to leverage the differences to identify mechanisms by which the CHIP protein may prove to be irreplaceable for long-term survival. We hypothesize that the CHIP KO proteomic profile will reveal changes critical to mitochondrial function, whereas the Parkin KO proteomic profile would reveal changes more in line with events that may only result in pathology after several decades. For instance, LDH is decreased in Parkin KO cortices, while PDH is increased e the opposite of findings in CHIP KO animals (Periquet et al., 2005) . Moreover, a critical subunit of Krebs cycle enzyme succinate dehydrogenase is increased in Parkin KO (Periquet et al., 2005) , while Krebs cycle enzymes in our CHIP KO screen are decreased. Taken together, these data underscore a compensatory role for Parkin mutated cells to increase metabolic pathways as a mechanism to deal with redox imbalance and protein oxidation. On the other hand, proteomic profiles from CHIP KO mice, wherein numerous energetics enzymes are decreased, suggest that these animals are unable to compensate. In combination with decreases in overall ATP levels in CHIP KO mice (Palubinsky et al., 2015) , we suspect that these changes underlie the severe motor and behavioral phenotypes of CHIP-deficient mice.
CHIP regulates mitochondrial morphology
Mouse embryonic fibroblasts (MEFs) generated from CHIP KO mice have distinct changes in mitochondrial morphology and cristae ultrastructure. Deletion of Parkin in mice (Palacino et al., 2004) and zebrafish (Flinn et al., 2009 ) results in no gross changes in mitochondrial morphology. In our hands, CHIP KO MEFs have condensed mitochondria with decreased matrix volume and fewer cristae in comparison to WT MEFs, which exhibit increased matrix volume and an inner membrane folded into organized cristae (Fig. 2) . Cristae typically become more tightly folded in cells with higher bioenergetic requirements, and disruption of the mitochondrial cristae and cristae junctions that stabilize folding is associated with chemo-osmotic impairments. These data are consistent with our observation that CHIP KO mitochondria swell and lyse in response to calcium challenges that are non-lethal in organelles derived from wild-type animals (Palubinsky et al., 2015) . Assembly of structurally stable and functional respiratory chain complexes within the folds of the inner mitochondrial membrane is also highly dependent upon cristae shape (Cogliati et al., 2013) . Alterations and remodeling of inner membrane structures are evident in numerous human disorders in which they often result in the accumulation of mitochondrial matrix aggregates (Zick et al., 2009 ). These observations are consistent with altered cristae formation, as well as mitochondrial fission and fusion abnormalities observed in CHIP KO MEFs (Fig. 3A and C) .
Mitochondrial fission reactions are regulated by Drp1, mitochondrial fission factor (Mff), and mitochondrial fission 1 protein (Fis1). These proteins are key in proper mitochondrial maintenance as they can affect the size, shape, and distribution of these organelles (Reddy et al., 2011) . Our proteomics analysis reveal increases in 'pro-fission' molecules in samples from CHIP KO mice. This suggests that they may be substrates of CHIP E3 ligase activity, much like mitofusin 1 & 2 have been found to be substrates of Parkin-mediated degradation (Gegg et al., 2010) .
Our proteomic data also reveals PHB, PHB-2 and lysocardiolipin acyltransferase are decreased in CHIP-deficient CNS. Prohibitins (PHBs) have roles in regulating normal aging and inflammatory processes, and loss of PHB function is associated with numerous diseased states that include obesity, cancer, stroke, PD and Alzheimer's disease (Ferrer et al., 2007; Kurinami et al., 2014; Merkwirth and Langer, 2009a; Merkwirth et al., 2012) . Prohibitin complexes control cell proliferation, cristae morphogenesis and mitochondrial integrity (Merkwirth and Langer, 2009b) . Functional PHB complexes also control assembly of the respiratory chain, activation of fusion, and the integrity of mitochondria and overall cellular health, as decreases in prohibitin have been correlated with increased generation of ROS and increased susceptibility to cell death (Kurinami et al., 2014; Zhou et al., 2012) .
PHB scaffolding also plays a crucial role in the processing of OPA1, a critical component of mitochondrial fusion machinery and this process is impaired in the absence of the scaffold provided by PHBs (Merkwirth et al., 2008) . Interestingly, destabilization of the long form of OPA1 has been observed in cells lacking m-AAA proteases (Ehses et al., 2009) , mutations in which are linked to ataxias (Pierson et al., 2011) . These data support our hypotheses that fusion/fission machinery is abnormal in CHIP KO animals and contribute to their severe motor impairment (Palubinsky et al., 2015) .
Trafficking of PHBs to mitochondrial lipids relies heavily upon the oxidative environment to which cells are exposed. For example, PHBs typically bind strongly to PIP3; however, under conditions of oxidative stress, PHBs instead have a higher affinity for cardiolipin (Sripathi et al., 2011) . These data suggest that these mitochondrial specific, typically 'pro-fusion' proteins may be responding to the overall cellular environment, wherein loss of CHIP results in increased oxidative protein damage, decreased cellular energetics, dysregulated calcium buffering capabilities and increased susceptibility to stress (Palubinsky et al., 2015) (Fig. 3) . In such a scenario, we hypothesize that the diminished pool of healthy mitochondria forces neurons to prioritize preservation of their remaining mitochondria. This strategy may be key for survival, thus dramatically shortening the life span of CHIP-deficient animals given the changes in expression of proteins linked to ATP generation in CHIP KO mice. While the fission/fusion/energetic remodeling found in CHIP KO animals is also hypothesized to occur in low levels in Parkin deficient animals (Periquet et al., 2005) , it is nowhere near as extreme as when CHIP is deleted.
Taken together these data support our present findings that mitochondria from CHIP KO mice demonstrate aberrant morphology via EM (Fig. 2 ) and suggest these changes may be due to improper fusion and/or uncontrolled fission.
Structural determinants of Parkin regulation of mitochondrial quality control
Beyond SNpc specific neurochemistry, firing and development, Parkin and PD-associated proteins play critical roles in mitochondrial function. Drosophila with mutated Parkin exhibit muscle dysfunction and swollen mitochondria, and Parkin co-localizes to these mitochondria as they are actively undergoing energetic failure (Greene et al., 2003; Narendra et al., 2008) .
Parkin and PINK1 interact to regulate mitophagy
The selective degradation of mitochondria is a multi-tiered system that can be triggered by single events or combination of stressors. Two distinct steps facilitate mitophagy: the priming of autophagic proteins and the selection of mitochondria for recycling (Ding et al., 2010; Egan et al., 2011; Greene et al., 2012; Itakura et al., 2012) .
Genetic studies reveal that Parkin works closely with another gene that is altered in familial forms of PD, PTEN-inducible putative kinase 1 (PINK1) to control mitochondrial degradation via autophagy (mitophagy). PINK1 is a serine-threonine kinase that is constitutively synthesized and imported to all mitochondria, but cleaved from healthy mitochondria by inner-membrane proteases (Greene et al., 2012) . In mitochondria that fail to maintain membrane potential, PINK1 accumulates on the OMM, where its catalytic kinase domain is exposed and able to phosphorylate OMM proteins as a signal for Parkin-mediated ubiquitination (Lazarou et al., 2013; Narendra et al., 2010) . PINK1 can also phosphorylate the linker region of Parkin itself, facilitating the mitochondrial translocation of this E3 ligase (Kim et al., 2008) .
Whereas many PD-and Parkinsonian-linked genes affect either fission or fusion related proteins, the proteins that promote engulfment, dynamic changes in mitochondrial number and function, and compensation of the dopaminergic circuit that results in decades-long decline and motor manifestation of disease require a great deal more of study. For example, Nix proteins expressed on the OMM are a physical tether between mitochondrial lipid membranes and engulfing autophagosomes speckled with LC3 and GABARAP (Ding et al., 2010; Novak et al., 2010) . This engulfment and the processes that precede it can occur in the absence of mitochondrial depolarization, which is often depicted as the common trigger of mitophagy. Indeed, any number of cues such as signaling via the outer membrane kinase Ulk1 (Itakura et al., 2012; Lazarou et al., 2015) , as well as the cytosolic chaperones HSP90 and Cdc37 (Joo et al., 2011; Weihofen et al., 2008) and the Nix-like protein Bnip3 , and triggers of the mitochondrial unfolded response (discussed later) can all promote mitochondrial fission and Parkin recruitment.
We have shown that CHIP is induced by acute neurologic stress but the molecular cues that promote CHIP translocation to mitochondria remain to be identified (Palubinsky et al., 2015) . Our preliminary data using point mutations in either the TPR domain or Ubox domain that impair the ubiquitination and HSP70 interacting properties of CHIP remain capable of moving to the mitochondria under acutely neurotoxic conditions (Lizama et al., Under Review) . Patients with a history of transient ischemic attack or ischemic stroke exhibit increased CHIP expression (Stankowski et al., 2011) . (Lizama et al., Under Review) . Proteomic data from 2-month-old Parkin KO mouse cortices are described by Periquet and colleagues (Periquet et al., 2005) . A. Diagram summarizing proteins altered by either CHIP KO or Parkin KO. Proteins increased in CHIP KO mice are labeled in red, while proteins decreased by CHIP loss are labeled in blue. Proteins increased in Parkin KO mice are labeled in green, while proteins decreased by Parkin loss are labeled in purple. B. Glycolytic enzymes pyruvate dehydrogenase (PDH) and lactate dehydrogenase (LDH) are increased and decreased, respectively, while mitochondrial pyruvate carrier proteins I and II (MPC1/MPC2), which affect pyruvate uptake into mitochondria, are increased by CHIP loss. Acyl CoA synthases II and III (ACSS2/ACSS3) are increased in CHIP KO. Loss of CHIP decreases expression of the Krebs cycle enzymes 2-oxoglutarate dehydrogenase (aKGDH), malonyl-CoA decarboxylase (MCD), and d-2-hydroxyglutarate dehydrogenase (D2-HGD). FAD-dependent oxidoreductase protein I (FOXRED1), which is crucial for respiratory complex 1 formation, is also decreased in CHIP KO. C. A key enzyme in cardiolipin localization and formation, lysocardiolipin acyltransferase (ALCAT1), is decreased in CHIP KO mice. Similarly, prohibitins (PHB1/PHB2), known to control cristae morphogenesis and respiratory chain assembly as well as to dictate levels of ROS within mitochondria via interactions with cardiolipin are also decreased when CHIP is absent. Three key fission proteins, dynamin-related protein 1 (Drp1), mitochondrial fission factor (Mff) and mitochondrial fission 1 protein (Fis1) are increased in CHIP KO mice.
Likewise, in vitro models of ischemia and heat shock promote CHIP expression and localization to mitochondria (Palubinsky et al., 2015) .
Acute stress induced by environmental toxins or bioenergetic dysfunction also increases the mitochondrial retention of full length PINK1 whereas total Parkin expression remains unchanged . Our data supports a model whereby CHIP, like Parkin, is recruited to mitochondria during acute stress through PINK1 stabilization and kinase activity.
Parkin facilitates mitophagy via specific structural domains
The specific structural elements of Parkin that contribute to mitochondrial translocation suggest that the RING1 domain is a critical modulator of relocalization. Overexpression of RING1 mutants fail to rescue the mitochondrial morphological changes observed in KO animals, indicating that the RING1 domain is necessary . While the UBL region is mutated in some patients with familial PD, Parkin does not require the UBL domain or the linker region to localize to mitochondria. Both the regulatory RING0 domain and the complete carboxy-terminal RING configuration of Parkin are also required for both mitochondrial translocation and subsequent mitochondrial degradation by mitophagy (Geisler et al., 2010) .
In Drosophila, Parkin translocation is dependent on phosphorylation of residues S65, T175 and T217, but phosphorylation at these sites is not sufficient (Kane et al., 2014; Narendra et al., 2010) . These data suggest that RING1 and UBL domain phosphorylation are critical regulators of Parkin translocation. How these posttranslational modifications influence Parkin structure and activity remained elusive until the discovery of PINK1-mediated phosphorylation of ubiquitin.
In 2015, three research groups found that PINK1 phosphorylates Ser65 on ubiquitin molecules (pS65-Ub) ligated to proteins on the OMM. Phospho-ubiquitin then binds to Parkin's RING1 domain, inducing a conformational change that allows PINK1-mediated phosphorylation of Ser65 in the UBL domain of Parkin. This creates an "open" state of Parkin that allows for increased E3 ligase activity and releases it from its autoinhibited state where the UBL is blocking the RBR core and promoting PINK phosphorylation of the S65 site (Aguirre et al., 2017; Kane et al., 2014; Kazlauskaite et al., 2014; Koyano et al., 2014; Nguyen et al., 2016 ).
An alternative strategy to target E3 ligases is by altering the post-translational modifications (PTMs) of these proteins. For example, phosphorylation of Parkin at Ser65 via PINK1 and other serine sites is required for its activation and ubiquitinating abilities (Kazlauskaite et al., 2014; Sha et al., 2010) . Similarly, phosphorylation at Tyr143 via Abl inhibits Parkin's E3 ligase activity , suggesting that both 'stop' and 'go' signals could be regulated pharmacologically. Understanding the compensatory pathways for mitochondrial quality control may be key to treating PD and other acute CNS injury in which early responders to mitochondrial stress like PINK1/Parkin fail.
Many in vitro and Drosophila models of null or mutated PINK1 do not exhibit stress-induced Parkin translocation to failing mitochondria (Song et al., 2013) . Additionally, much like Parkin KO animal models, mice deficient in PINK1 fail to exhibit an overt behavioral phenotype or PD pathology (Kitada et al., 2009 ). The PINK1 deficient animal models share more in common with Parkinnull animals than any other E3 ligase mutants or knockouts (Gispert et al., 2009 ). This suggests that there is specificity in PINK1-Parkin binding and signaling, and that these proteins have a preferred interaction. Therefore, simply overexpressing another E3 ligase to rescue Parkin loss of function is ill-advised (Stankowski et al., 2011 ). Yet PINK1 and Parkin mutants can be useful in understanding biochemical changes at the level of mitochondria. For example, Parkin-mediated mitochondrial fragmentation can be abolished by inhibiting the calcium/calmodulin/calcineurin signaling pathway, suggesting that fragmentation requires dephosphorylation of Drp1 (Buhlman et al., 2014) . It is perhaps not surprising that Parkin deletion does not alter baseline mitochondrial morphology in mice. Indeed, mitophagy can proceed unfettered in Drp1 KO animals. In studies by Kageyama and colleages, mitochondrial ubiquitination and localization of the autophagy adaptor protein, p62, occurred independently of Parkin (Kageyama et al., 2014) .
Parkin regulates the mitochondrial-specific unfolded protein response
Until recently, models of PINK1/Parkin-dependent mitochondrial quality control and mitophagy have been studied using by mitochondrial membrane potential uncouplers and electron transport chain inhibitors Narendra et al., 2010) . Indeed, both PINK1 and Parkin respond to membrane potential depolarization, but they have recently been shown to respond to more subtle defects in both cytosolic and mitochondrial protein homeostasis ). This in turn promotes the accumulation of full-length PINK1 and Parkin translocation in polarized mitochondria .
Changes in mitochondrial membrane potential are short-lived and mitochondria face a variety of challenges beyond depolarization. Localized mitochondrial depolarization where proteins are being actively imported and exported to regulate cell viability and proteotoxic stress within the mitochondria may be a factor that plays a significant role in the long-term health of neurons (Brady et al., 2004) .
Models of PD exhibit decreases or dysfunction in components of the mitochondrial-specific unfolded protein response (UPRmt), which are also consistent with observations in patients with PD. Mitochondrial chaperones that are found to interact with Parkin include HSP60, TNF Receptor-Associated Protein 1 (TRAP1), and Mortalin. Overexpression of a mutated form of ornithine transcarbamylase (OTC) in cell culture induces protein misfolding and aggregation in mitochondria. When mitochondria are stressed by factors that impair protein folding, the UPRmt is initiated and mitochondrial signals are sent to the nucleus to upregulate mitochondrial chaperones and proteases (Liao et al., 1991; Pellegrino and Haynes, 2015) . Data from current models of mitochondrial quality control suggest that PINK1/Parkin-mediated mitophagy clears dysfunctional mitochondria when protein misfolding and aggregation extends beyond the capacity of the UPRmt (Pellegrino and Haynes, 2015) .
HSP60 triggers mitophagy through Parkin
The HSP60/HSP10 chaperonin complex is a major component in the UPRmt. Under basal conditions, HSP60 folds newly imported mitochondrial proteins and assembles protein complexes within the matrix (Pellegrino and Haynes, 2015) . Heat shock and other cell stressors induce HSP60 protein expression, which then aids in the refolding of damaged matrix proteins and in preventing protein aggregation. Mutations in HSP60 were identified in patients with inherited spastic paraplegia and with an inherited white matter disorder known as MitCHAP60 -both of which are diseases exclusive to the CNS (Magnoni et al., 2013) . Additionally, HSP60 protein in a 6-OHDA rat model of PD is decreased in SNpc neurons (Feng et al., 2013) .
Given that many neurodegenerative diseases, including PD, encompass mitochondrial dysfunction, which the HSPs typically combat (summarized and reviewed in (Jha et al., 2017) ), therapeutic targeting of these molecules seems an important clinical modality to explore further (Pratt et al., 2015) .
TRAP1 and Mortalin maintain mitochondria via parallel functions to Parkin
TRAP1 is a mitochondrial protein that is a member of the HSP90 family, and named for its interaction with Tumor Necrosis Factor Receptor type 1, a membrane receptor activated by TNF-alpha. TRAP1 was the first identified in vivo target of PINK1 phosphorylation and is involved in maintaining mitochondrial polarization, ETC complex stabilization, and in controlling the gating of the mitochondrial permeability transition pore Pridgeon et al., 2007; Zhang et al., 2013) . As such, TRAP1 KO mice exhibit deregulated mitochondrial respiration and increased mitochondrial protein misfolding Lisanti et al., 2014) .TRAP1 is an appealing therapeutic target as overexpression of this protein is able to rescue PINK1 loss of function, and partially rescues mitochondrial deficits (but not impaired motor performance) in Parkin-null Drosophila models . Moreover, overexpression of Parkin rescues TRAP1 mutants, suggesting that TRAP1 and Parkin may have similar or parallel functions . Lastly, TRAP1 overexpression in cortical and human dopaminergic neuronal cultures protects cells from asynuclein-induced toxicity (Butler et al., 2012) .
Mortalin, or HSPA9, is a conserved member of the HSP70 family. Mortalin is decreased in the SNpc of patients with PD, and in vitro studies found that deficient Mortalin leads to a loss of mitochondrial membrane potential and activation of the UPRmt (Burbulla et al., 2014; Cook et al., 2016) . The mitochondrial failure that occurs in Mortalin null cells can be rescued by overexpression of Parkin and PINK1, which stimulate mitophagy (Burbulla et al., 2014) . In this way, Parkin assists in preventing mitochondrial dysfunction and subsequent cell death caused by misfolded protein aggregation.
These data demonstrate that mitochondrial chaperones and the PINK1/Parkin mitophagic response converge on dysfunctional mitochondria. Given these overlaps, elucidating the pathways involved in the mammalian UPRmt is imperative to the development of therapies targeting mitochondrial quality control.
7. Therapeutic targets and the challenges of reducing CHIP and Parkin-mediated pathology
Opportunities for targeting E3 ligases with off-Label drugs
Targeting the UPS has proven successful for the treatment of multiple myeloma and other types of cancer (Ghobrial et al., 2016; Guang and Bianchi, 2017) . The first FDA approved proteasome inhibitor, bortezomib, binds to the 20S proteasome to block the degradation of pro-apoptotic proteins, inducing cell cycle arrest (Accardi et al., 2015; Piperdi et al., 2011) . Since the approval for use of this landmark drug in 2003, several other proteasome inhibitors have been approved or are in late-stage clinical trials (Manasanch and Orlowski, 2017; Teicher and Tomaszewski, 2015) . Although these drugs maintain high specificity and efficacy, proteasome inhibitors are not pathway-specific, targeting the latter steps of the UPS during which all protein degradation is affected.
Upon dissociation from HSP70, Parkin also promotes degradation of the Pael-R receptor during times of ER-stress (Imai et al., 2002) . This positive regulation of Parkin via the HSP70 chaperone complex, as well as an increasing number of disease states in which chaperone machinery and the UPS are disrupted (Charan and LaVoie, 2015) , again suggests that E3 ligases may be potential therapeutic targets. Further support for E3s as drug targets comes from studies of proteasome inhibition with bortezomib (Ruschak et al., 2011) or carfilzomib (Kuhn et al., 2007) , which, while effective, were shown to result in broad toxicity, off-target effects and increased drug resistance, suggesting that enzymes that lie upstream of the proteasome, such as E3 ligases, are a more feasible target (Bulatov and Ciulli, 2015; Goldenberg et al., 2010; Huang and Dixit, 2016) . Additionally, E3 ligases represent an attractive drug target due to the limited number of substrates they target, limiting the regulatory pathways affected (Bhowmick et al., 2013; Bulatov and Ciulli, 2015; Huang and Dixit, 2016; Skaar et al., 2014 ). Yet, to date only two inhibitors, Nutlins (Roche) and Lenalidomide (Celgene) for the E3 ligases MDM2 and CRBN, respectively, have reached clinical trials (Patel and Player, 2008; Skaar et al., 2014) .
One biochemical feature of RBR E3s that makes them slightly more complex to inhibit compared to other E3s is that they require disruption of strong protein-protein interactions, which is more difficult than simply targeting a catalytic site (Arkin et al., 2014; Gonzalez-Ruiz and Gohlke, 2006) . A notable biochemical difference of RBR E3 ligases is that they act as scaffolds or adaptors to bring the components of the ubiquitination machinery in closer contact with the substrate. In doing so, the ubiquitin-conjugated E2 binds to the RING1 domain and then ubiquitin is transferred from the E2 to the E3 RING2 domain from which it is then transferred to the substrate (Bielskiene et al., 2015) . Therefore, inhibiting the activity of RBR E3s requires molecules that interrupt the interaction between the ubiquitinated substrate at the substrate interaction domain in order to selectively block degradation of a small number of client proteins (Patel and Player, 2008) .
While issues remain with generating specific and effective targets of RBR E3s, the fact that Parkin assumes a unique conformation and is subject to numerous inhibitory and activating posttranslational modifications provides additional avenues for therapeutic design (Chakraborty et al., 2017; Rubio de la Torre et al., 2011) . At baseline, Parkin exists in an auto-inhibited state (Trempe et al., 2013) wherein ultimately, its E2 binding site is blocked. However, the ubiquitin ligase domain of Parkin can inhibit its auto-ubiquitination activities (Chaugule et al., 2011) . Therefore the development of small molecule modulators that result in a conformational change that exposes typically hidden sites or buries inhibitory domains may subsequently lead to Parkin activation and ubiquitination of damaged client proteins (Caulfield et al., 2015) . In generating therapeutic strategies for modifying E3 ligase activity, it is important to verify which models use naturally-occurring versus synthetic mutants to divulge E3 ligase functions. For example, Parkin mutant C431S is not found in patients with PD, but its use in cell culture models identified a covalent intermediate in Parkin activation and evidence for its HECT-like activity (Lazarou et al., 2013) .
Controlling chaperone activity to dictate protein fate
Beyond direct control over E3 ligases and their PTM sites, an alternate strategy to change E3 expression and activity is to change the catalogue of clients presented for ubiquitination and the activity of the chaperone complex. Heat shock proteins (HSPs) constitute a highly conserved and functionally interactive network of chaperone proteins. While some HSPs are constitutively expressed, others are inducible in response to chemical, environmental and physiological stressors. Collectively, HSPs work to disaggregate, refold, and renature misfolded proteins in order to avoid otherwise fatal consequences. As such, many KO models of heat shock proteins themselves, the major HSP transcription factor, HSF1, and HSP co-chaperones exhibit severe abnormalities in their cardiovascular, reproductive and nervous systems, decreased growth rates and overall body size and increased aging phenotypes, all of which often lead to early mortality (Dickey et al., 2008; Hashimoto-Torii et al., 2014; Kim et al., 2013; Min et al., 2008; Wacker et al., 2009) .
Given the role of HSPs in combating such a wide variety of cellular stressors, it is not surprising that much research has focused on developing modulators to inhibit or activate these key proteins (Holzbeierlein et al., 2010; Neckers and Workman, 2012) . The most specific and efficient compounds currently available are designed to target the structural components of HSP90, a chaperone that responds to a plethora of environmental and physiological stressors (Schopf et al., 2017) . Investigators initially established HSP90 0 s ability to be manipulated by drugs such as geldanamycin and radicicol. These natural small molecules mimic the ATP-bound structure adopted in the chaperone's N-terminal nucleotide binding domain (NBD) and cause potent and selective blockade of ATP binding/hydrolysis, inhibition of chaperone function, depletion of oncogenic clients, and antitumor activity (Neckers and Workman, 2012) .
Chaperone proteins exhibit high levels of structural conservation. For example, eleven members of the HSP70 family contain an N-terminal NBD (~40 kDa) and a C-terminal substrate-binding domain (SBD) of roughly 25 kDa connected by a short linker (Bertelsen et al., 2009 ). Similar to HSP90, HSP70 has unique structural components making it a suitable drug target. Many of the functions of HSP70 appear to revolve around crosstalk between ATPase activity in the NBD and substrate binding in the SBD. HSP70 binds tightly to ATP, and through an allosteric, interdomain interaction, increases the on-and off-rate of peptide binding in the adjacent SBD. In turn, nucleotide hydrolysis to ADP closes the "lid" and enhances the affinity for substrate. Likewise, interactions between the SBD and its substrates increase the rate of ATP hydrolysis in the NBD, suggesting that communication between the two domains is two-way (Mayer et al., 2000) . From a drug discovery viewpoint, this unique allostery provides multiple opportunities for chemical intervention, including inhibition of ATP turnover, substrate binding, or even blocking interdomain allostery altogether (Evans et al., 2010) .
The first set of specific allosteric modulators of the HSC70 complex that target the HSP40-HSC70 interacting or the ATP/ADP substrate binding domains have been developed. Importantly, these regions are conserved across all members of the HSC70 family, including HSP70. The ATP binding domain is a critical determinant of chaperone complex activity. When HSC70 family members bind HSP40, repetitive cycles of substrate binding and release occur. The affinity of ATP binding, length of substrate interaction and strength of substrate affinity therefore determines the fate of the client protein by modulating protein refolding or degradation. When bound to the nucleotide site, pro-degradation compounds block ATP turnover and drive the complex to release denatured proteins for subsequent ubiquitination and degradation. One of these compounds, MKT-077, is being actively explored in preclinical and clinical trials as it blocks proliferation of cancer cell lines (Li et al., 2013) . On the other hand, protein-refolding modulators activate the ATPase domain of HSP40 resulting in the constant clamping and release of HSP70-bound substrates required for proper protein refolding (Jinwal et al., 2009) . It is interesting to speculate as to what role Parkin may play when these compounds are administered.
HSPs also indirectly regulate mitochondrial dynamics in mutant models of Parkin. For example, expression of DnaJ/Hsp40 chaperone HSJ1a and DnaJB6 was found to rescue mitophagy of depolarized mitochondria in cultures expressing a Parkin RING domain mutant . This C289G mutation, found in patients with early-onset autosomal-recessive parkinsonism, causes Parkin to aggregate and lose the ability to translocate to mitochondria (Lucking et al., 2000) . HSP70 co-chaperones HSJ1a and DnaJB6 selectively prevented mutated Parkin from forming aggregates . A later study found conflicting data in which expression of these co-chaperones reduced aggregated mutant Parkin, but did not rescue mitophagy (Kakkar et al., 2016) . The authors attributed these conflicting results to the use of different cell lines with differential endogenous Parkin expression. Nevertheless, DnaJ proteins were effective in preventing mutant Parkin aggregation in an HSP70-dependent manner (Kakkar et al., 2016) . Therefore, targeting the expression or HSP70-binding capacity of DnaJ co-chaperones may be an additional opportunity for treating PD and other neurodegenerative diseases caused by aggregateprone E3 ligases.
Beyond targeting chaperones themselves, transcription factors that influence the expression of chaperones may also be able to regulate E3 function and activity both directly and indirectly. For example, under basal physiological conditions, HSF1 is an inactive monomer held in a multiprotein complex that includes HSC/HSP70 and HSP90 (Morimoto, 1998) . During heat stress, HSF1 undergoes a conformational change, trimerizes, and interacts directly with CHIP (Kim et al., 2005) . This interaction allows HSF1 to localize to the nucleus and induce HSC/HSP70 expression (Dai et al., 2003; Kim et al., 2005) . Thus, perhaps targeting HSF1 by promoting trimerization and subsequent binding with CHIP is a promising therapy to upregulate neuroprotective HSP70.
Activation of HSF1 occurs uniformly in response to treatment with the HSP90 inhibitors currently under clinical evaluation. While simultaneously inhibiting the oncogenic Ras/Raf signaling pathways, these agents also promote production of soluble and insoluble HSP70 pools (Bagatell et al., 2000) .
In neural cells, aggregation of mutant a-synuclein was shown to inhibit HSF1 expression by increasing its ubiquitination via the E3 ligase NEDD4 (Kim et al., 2016) . Conversely, introduction of a constitutively active form of HSF1 rescues neural cells from asynuclein-induced toxicity (Liangliang et al., 2010) . As such, efforts are currently underway to identify and validate modulators of HSF1, HSP70, and HSP27 and to explore their functions and validity in combination therapy with HSP90 and other chaperone inhibitors.
CNS drug discovery remains a challenge owing to issues of bloodebrain barrier penetrance, first-pass metabolism, target affinity and selectivity, and therapeutic index (Abbott, 2013; ButlenDucuing et al., 2016; Chico et al., 2009 ). The more we uncover about the structure, function and activity of Parkin and CHIP, where known mutations result in devastating disease, the more avenues we open regarding how to effectively target and treat neurodegeneration.
